

Therapy	FDA Indication	FDA Approval
Allacord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.	5.30.2013
Breyanzi®	Treatment of adult patients with relapsed or refractory large 8- cell lymphoma after two or more lines of systemic therapy, including diffuse large 8-cell lymphoma (DL8CL) not otherwise specified (including DL8CL arising from indolent lymphoma), high-grade 8-cell lymphoma, primary mediastinal large 8-cell lymphoma, and follicular lymphoma grade 3B	2.5.2021
Clevecord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	9.12.2016
Ducord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	10.04.2012
Gintuit®	Mucogingival conditions in adults	3.09.2012
Hemacord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	11.10.2011
HPC, Cord Blood (Clinimune Labs)	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	5.24.2012
HPC, Cord Blood (MD Anderson Cord Blood Bank)	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	
HPC, Cord Blood (LifeSouth)	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.	
HPC, Cord Blood (Bloodworks)	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.	2016

Source: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-andgene-therapy-products>

Therapy	FDA Indication	FDA Approval
Imlygic®	Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.	10.27.2015
Kymriah®	B-cell precursor Acute Lymphoblastic Leukemia (ALL) that is refractory or in second or later relapse in patients < 25 years old Indicated to treat relapsed or refractory Large B-cell Lymphoma (a type of Non-Hodgkin Lymphoma) after > 2 lines of systemic therapy.	5.1.2018
	Indicated to treat B-cell precursor Acute Lymphoblastic Leukemia (ALL) that is refractory or in second or later relapse in patients < 25 years old.	8.30.2017
	Age 18 and older with refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A).	5.27.2022
Laviv®	Improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.	6.21.2011
Luxturna®	Confirmed biallelic RPE65 mutation-associated Retinal Dystrophy in adults and children > 1 year that have viable retinal cells	12.19.2017
Maci®	Repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.	12.13.2016
Provenge®	Asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.	4.29.2010
Rethymic®	For the treatment of congenital athymia	10.08.2021
Stratagraft®	For the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).	6.15.2021
Skysona®	Indicated to slow the progression of neurologic dysfunction in early, active Cerebral Adrenoleukodystrophy (CALD) in boys 4-17 years old	9.16.2022
Tecartus®	Relapsed or refractory Mantle Cell Lymphoma in adults	7.24.2020
	Adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	10.21.2021

Source: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-andgene-therapy-products>

Therapy	FDA Indication	FDA Approval
Yescarta®	Relapsed or refractory Large B-cell Lymphoma (a type of Non-Hodgkin Lymphoma) in adults after two or more lines of systemic therapy. Includes Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified, primary Mediastinal Large B-cell Lymphoma, High Grade B-cell Lymphoma, and DLBCL arising from Follicular Lymphoma (types of Non-Hodgkin Lymphoma)	10.18.2017
	Indicated to treat relapsed or refractory Follicular Lymphoma (a type of indolent Non-Hodgkin Lymphoma) in adults after ≥ 2 lines of systemic therapy	3.5.2021

Source: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-andgene-therapy-products>



**PartnerRe America Insurance Company**  
 Phone +1 612 234 4920

[www.partnerre.com/health](http://www.partnerre.com/health)